Skip to main content

Advertisement

Table 2 Central and peripheral hemodynamic data during pulse wave analysis in patients with and without metabolic syndrome

From: Association of HIV-infection, antiretroviral treatment and metabolic syndrome with large artery stiffness: a cross-sectional study

  No Metabolic Syndrome Metabolic Syndrome
Variable Controls HIV-1 untreated HIV-1 cART Controls HIV-1 untreated HIV-1 cART
(n = 39) (n = 32) (n = 42) (n = 10) (n = 16) (n = 12)
Central systolic BP 113 ± 12 116 ± 10 114 ± 10 126 ± 7c 120 ± 13 110 ± 11b
Peripheral systolic BP 123 ± 13a 127 ± 11a 124 ± 11a 135 ± 7ac 129 ± 11a 120 ± 13a
Central diastolic BP 75 ± 7 78 ± 6 78 ± 8 81 ± 3c 78 ± 6 74 ± 7b
Peripheral diastolic BP 74 ± 7a 77 ± 6a 76 ± 8a 79 ± 3ac 72 ± 7a 72 ± 7ab
Central MAP 87 ± 8 91 ± 7 90 ± 9 96 ± 3c 92 ± 7 86 ± 8b
Peripheral MAP 90 ± 8a 93 ± 7a 92 ± 8a 98 ± 2ac 94 ± 7a 87 ± 8bc
Central PP 38 ± 9 38 ± 8 36 ± 7 45 ± 8c 41 ± 9 36 ± 8
Peripheral PP 49 ± 10a 50 ± 10a 47 ± 7a 56 ± 9a 52 ± 9a 45 ± 8ab
PP amplification (ratio) 1.33 ± 0.17 1.33 ± 0.14 1.32 ± 0.13 1.24 ± 0.12 1.29 ± 0.12 1.25 ± 0.19
Heart rate (beats/min) 67 ± 11 76 ± 10b 74 ± 11b 66 ± 7 74 ± 6 78 ± 13b
  1. Values (mmHg) are means ± SD. cART combined antiretroviral therapy, BP blood pressure, MAP mean arterial pressure, PP pulse pressure, aP < 0.001 for within-group central variable, bP < 0.01 versus within-group controls, cP < 0.001 vs. no metabolic syndrome controls